Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STK39 | Q9UEW8 | 7/20 | 0.63 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.57 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.57 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.57 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | NPC1 | O15118 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | RAB9A | P51151 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.55 |
| ▸ | ACLY | P53396 | 2/20 | 0.54 |
| ▸ | GFER | P55789 | 1/20 | 0.51 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11692717 | 0.84 | PTGS1 (0.71) | STK39PTGS1TBXAS1MAPK1PTGS2 | |
| SCHEMBL11887644 | 0.82 | KCNMA1 (0.68) | MAPK1MEN1MAPTKMT2AKDM4E | |
| SCHEMBL29617476 | 0.82 | KCNMA1 (0.68) | MAPK1MEN1MAPTKMT2AKDM4E | |
| SCHEMBL29459607 | 0.82 | RAB9A (0.67) | MEN1MAPTKMT2AKDM4ENPC1 | |
| SCHEMBL11219138 | 0.82 | RAB9A (0.67) | MEN1MAPTKMT2AKDM4ENPC1 | |
| SCHEMBL25395048 | 0.81 | MAPT (0.66) | MAPK1MEN1MAPTKMT2AKDM4E | |
| SCHEMBL28392557 | 0.81 | HSPA5 (0.64) | STK39PTGS1TBXAS1MAPK1PTGS2 | |
| SCHEMBL22089468 | 0.80 | MEN1 (0.60) | MAPK1PTGS2MEN1MAPTKMT2A | |
| SCHEMBL29936212 | 0.80 | MAPT (0.73) | STK39PTGS1TBXAS1MAPK1PTGS2 | |
| SCHEMBL4263591 | 0.80 | MAPT (0.73) | STK39PTGS1TBXAS1MAPK1PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11793777-B2 | Methods and compositions for treating conditions associated with an abnormal inflammatory response | FIRST WAVE BIO, INC. (US) | 2023-10-24 | — | — | US | disclosed |
| US-11793777-B2 | Methods and compositions for treating conditions associated with an abnormal inflammatory response | FIRST WAVE BIO, INC. (US) | 2023-10-24 | — | — | US | disclosed |
| US-11331290-B2 | Niclosamide for the treatment of cancer metastasis | MAX-DELBRÜCK-CENTRUM FÜR MOLEKULARE MEDIZIN IN DER HELMHOLTZ-GEMEINSCHAFT (DE) | 2022-05-17 | — | — | US | disclosed |
| US-20220125807-A1 | PHARMACEUTICAL COMBINATION OF WNT SIGNALING AND MACC1 INHIBITORS | CHARITÉ - UNIVERSITÄTSMEDIZIN BERLIN (DE) | 2022-04-28 | — | — | US | disclosed |
| US-20220000812-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSES | FIRST WAVE BIO, INC. | 2022-01-06 | — | — | US | disclosed |
| US-20210401784-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSE | FIRST WAVE BIO, INC. | 2021-12-30 | — | — | US | disclosed |
| US-10912746-B2 | Methods and compositions for treating conditions associated with an abnormal inflammatory response | FIRST WAVE BIO, INC. (US) | 2021-02-09 | — | — | US | disclosed |
| US-10905666-B2 | Methods and compositions for treating conditions associated with an abnormal inflammatory response | FIRST WAVE BIO, INC. (US) | 2021-02-02 | — | — | US | disclosed |
| US-10849867-B2 | Methods and compositions for treating conditions associated with an abnormal inflammatory response | FIRST WAVE BIO, INC. (US) | 2020-12-01 | — | — | US | disclosed |
| US-10799468-B2 | Methods and compositions for treating conditions associated with an abnormal inflammatory responses | FIRST WAVE BIO, INC. (US) | 2020-10-13 | — | — | US | disclosed |
| US-20200197340-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSES | FIRST WAVE BIO, INC. | 2020-06-25 | — | — | US | disclosed |
| US-20200155484-A1 | NICLOSAMIDE FOR THE TREATMENT OF CANCER METASTASIS | MAX-DELBRÜCK-CENTRUM FÜR MOLEKULARE MEDIZIN IN DER HELMHOLTZ-GEMEINSCHAFT (DE) | 2020-05-21 | — | — | US | disclosed |
| US-20200147012-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSES | FIRST WAVE BIO, INC. | 2020-05-14 | — | — | US | disclosed |
| US-20200147013-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSES | FIRST WAVE BIO, INC. | 2020-05-14 | — | — | US | disclosed |
| US-20190298670-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSES | MONTERESEARCH S.R.L. (IT) | 2019-10-03 | — | — | US | disclosed |
| US-10292951-B2 | Methods and compositions for treating conditions associated with an abnormal inflammatory responses | FIRST WAVE BIO, INC. (US) | 2019-05-21 | — | — | US | disclosed |
| US-20170056347-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSES | FIRST WAVE BIO, INC. | 2017-03-02 | — | — | US | disclosed |
| US-20170056347-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSES | FIRST WAVE BIO, INC. | 2017-03-02 | — | — | US | disclosed |
| US-20140294957-A1 | NICLOSAMIDE FOR THE TREATMENT OF CANCER METASTASIS | MAXDELBRUCK-CENTRUM FUR MOLEKULARE MEDIZIN (DE) | 2014-10-02 | — | — | US | disclosed |
| US-20140294957-A1 | NICLOSAMIDE FOR THE TREATMENT OF CANCER METASTASIS | MAXDELBRUCK-CENTRUM FUR MOLEKULARE MEDIZIN (DE) | 2014-10-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (17 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210401784-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSE | FH, CS, ECHS1 | STK39 4243/4885PTGS1 195/4885TBXAS1 2138/4885 |
| US-20200147012-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSES | FH, CS, ECHS1 | STK39 4236/4885PTGS1 210/4885TBXAS1 2133/4885 |
| US-20190298670-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSES | FH, CS, ECHS1 | STK39 4241/4885PTGS1 209/4885TBXAS1 2151/4885 |
| US-10849867-B2 | Methods and compositions for treating conditions associated with an abnormal inflammatory response | FH, CS, ECHS1 | STK39 4243/4885PTGS1 195/4885TBXAS1 2138/4885 |
| US-20200197340-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSES | FH, CS, ECHS1 | STK39 4236/4885PTGS1 210/4885TBXAS1 2133/4885 |
| US-20140294957-A1 | NICLOSAMIDE FOR THE TREATMENT OF CANCER METASTASIS | S100A4, S100A11, S100A6 | STK39 4251/4885PTGS1 748/4885TBXAS1 2092/4885 |
| US-10799468-B2 | Methods and compositions for treating conditions associated with an abnormal inflammatory responses | FH, CS, ECHS1 | STK39 4241/4885PTGS1 209/4885TBXAS1 2151/4885 |
| US-10292951-B2 | Methods and compositions for treating conditions associated with an abnormal inflammatory responses | FH, CS, ECHS1 | STK39 4241/4885PTGS1 209/4885TBXAS1 2151/4885 |
| US-10912746-B2 | Methods and compositions for treating conditions associated with an abnormal inflammatory response | FH, CS, ECHS1 | STK39 4234/4885PTGS1 197/4885TBXAS1 2122/4885 |
| US-11331290-B2 | Niclosamide for the treatment of cancer metastasis | S100A4, S100A11, S100A6 | STK39 4242/4885PTGS1 735/4885TBXAS1 2613/4885 |
| US-20170056347-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSES | FH, CS, ECHS1 | STK39 4241/4885PTGS1 209/4885TBXAS1 2151/4885 |
| US-20220125807-A1 | PHARMACEUTICAL COMBINATION OF WNT SIGNALING AND MACC1 INHIBITORS | S100A4, CTNNBL1, CTNNB1 | STK39 3005/4885PTGS1 2409/4885TBXAS1 2317/4885 |
| US-20220000812-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSES | FH, CS, ECHS1 | STK39 4241/4885PTGS1 209/4885TBXAS1 2151/4885 |
| US-20200147013-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSES | FH, CS, ECHS1 | STK39 4241/4885PTGS1 209/4885TBXAS1 2151/4885 |
| US-20200155484-A1 | NICLOSAMIDE FOR THE TREATMENT OF CANCER METASTASIS | S100A4, S100A11, S100A6 | STK39 4242/4885PTGS1 735/4885TBXAS1 2613/4885 |
| US-10905666-B2 | Methods and compositions for treating conditions associated with an abnormal inflammatory response | FH, CS, ECHS1 | STK39 4243/4885PTGS1 195/4885TBXAS1 2138/4885 |
| US-11793777-B2 | Methods and compositions for treating conditions associated with an abnormal inflammatory response | FH, CS, ECHS1 | STK39 4243/4885PTGS1 195/4885TBXAS1 2138/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.